A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Venetoclax in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Polatuzumab Vedotin and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Latest Information Update: 27 Jun 2024
At a glance
- Drugs Obinutuzumab (Primary) ; Polatuzumab vedotin (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
Most Recent Events
- 27 Jun 2024 Results evaluated safety and efficacy of polatuzumab vedotin 1.8 mg/kg and venetoclax 800 mg, plus fixed-dose obinutuzumab 1000 mg or rituximab 375 mg/m2 in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL), published in the American Journal of Hematology
- 01 Mar 2023 Results published in the American Journal of Hematology
- 05 Aug 2022 Status changed from active, no longer recruiting to completed.